Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10209786 | 0.91 | ALDH1A1 (0.46) | TSHRCA2CA1CA7CA4 | |
| SCHEMBL10569435 | 0.83 | CA2 (0.54) | LMNATSHRMEN1KMT2ACA2 | |
| SCHEMBL13868981 | 0.82 | LMNA (0.65) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL18193737 | 0.81 | LMNA (0.66) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL10570309 | 0.81 | CA2 (0.48) | LMNATSHRCA2CA1CA7 | |
| SCHEMBL30096784 | 0.81 | CA2 (0.46) | LMNATSHRMEN1KMT2ACA2 | |
| SCHEMBL10209758 | 0.79 | ALDH1A1 (0.43) | LMNATSHRMEN1KMT2ACA2 | |
| SCHEMBL2198233 | 0.79 | ALDH1A1 (0.40) | LMNATSHRCA2CA1CA7 | |
| SCHEMBL2198241 | 0.79 | ALDH1A1 (0.40) | LMNATSHRCA2CA1CA7 | |
| SCHEMBL2198236 | 0.79 | ALDH1A1 (0.40) | LMNATSHRCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7518017-B2 | Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds | IDEXX LABORATORIES (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518017-B2 | Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds | IDEXX LABORATORIES (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1953138-A2 | Fenicol compounds and methods of synthesizing 2-trifluoracetamido-3-substituted propiophenone compounds | IDEXX LABORATORIES, INC. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070197823-A1 | Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds | IDEXX LABORATORIES, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197823-A1 | Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds | IDEXX LABORATORIES, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197823-A1 | Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds | ADRB1, ADRB2, ADRA1A | LMNA 1515/4885TSHR 525/4885MEN1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.